Investor Alert

New York Markets Open in:

Market Pulse Archives

Oct. 18, 2021, 8:55 a.m. EDT

Adamis Pharmaceuticals stock rockets on heavy volume after opioid overdose treatment gets FDA approval

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Adamis Pharmaceuticals Corp. (ADMP)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Adamis Pharmaceuticals Corp. /zigman2/quotes/205166351/composite ADMP -4.30% soared 20.4% on massive volume toward an eight-month high in premarket trading Monday, after the biopharmaceutical company said Zimhi, it's high-dose naloxone injection for the treatment for opioid overdose, has been approved by the Food and Drug Administration. Trading volume spiked to 32.8 million shares, enough to make the stock the most actively traded ahead of the open, and compared with the full-day average of about 2.0 million shares. "We are very excited by this approval and are working with our commercial partner, US WorldMeds, to make this much-needed, lifesaving product readily available to the market," said Adamis Chief Executive Dennis Carlo. "Zimhi provides the highest systemic levels of naloxone compared to any of the nasal or intramuscular products currently available." The stock has soared 132.9% year to date through Friday, while the iShares Biotechnology ETF /zigman2/quotes/206189322/composite IBB -0.42% has tacked on 3.7% and the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.04% has gained 19.0%.

US : U.S.: Nasdaq
$ 0.22
-0.0099 -4.30%
Volume: 492,409
Feb. 3, 2023 4:00p
P/E Ratio
Dividend Yield
Market Cap
$33.01 million
Rev. per Employee
US : U.S.: Nasdaq
$ 136.59
-0.58 -0.42%
Volume: 1.95M
Feb. 3, 2023 4:15p
-43.28 -1.04%
Volume: 0.00
Feb. 3, 2023 4:54p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.